RAPART trial for advanced lung cancer patients
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a treatment for stage 3 lung cancer that cannot be removed with surgery. It includes people who have had other treatments before, like chemo or immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer (a common type).
- Your cancer is stage 3 and cannot be surgically removed, or it became stage 3 after other treatments.
- Your daily activity level is good (ECOG score 0-2).
- You may have had prior treatments like surgery, chemo, immunotherapy, or targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with stage III lung cancer that cannot be removed with surgery. You would receive immunotherapy (to help your immune system fight cancer) plus chemotherapy first, then standard chemo-radiation, and finally more immunotherapy. The goal is to see if this sequence works better than standard treatment.
This trial tests a new drug called NBTXR3, which makes cancer cells more sensitive to radiation. You'll get one injection of NBTXR3 into your lung tumor, followed by standard radiation. It is for people with early-stage non-small cell lung cancer who cannot have surgery.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
This trial tests combining chemotherapy, radiation therapy, and two immune-boosting drugs (iparomlimab and tuvonralimab) as a first treatment for locally advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination improves outcomes compared to standard care.
This trial tests a newer, more precise way of giving radiation for lung cancer tumors that are near the center of the chest. The goal is to see if using a smaller treatment area can reduce side effects while still killing the cancer.
This Phase 1/2 trial tests RAPA-201, a personalized immune cell treatment made from your own T cells, for advanced solid tumors. It may help people whose cancer has come back after standard treatment and after an anti–PD-1/PD-L1 antibody.
Hear when a new Locally Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.